Qudexy XR FDA Approval History
FDA Approved: Yes (First approved March 11, 2014)
Brand name: Qudexy XR
Generic name: topiramate
Dosage form: Extended-Release Capsules
Company: Upsher-Smith Laboratories Inc.
Treatment for: Seizures, Lennox-Gastaut Syndrome, Migraine Prevention
Qudexy XR (topiramate) is an antiepileptic drug indicated for the treatment of partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut Syndrome in adults and children; and for the prophylaxis of migraine headache in adults and adolescents.
Development timeline for Qudexy XR
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
